EN DE
Watch Xtant Medical Holdings Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Xtant Medical Holdings Inc (XTNT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Xtant Medical Holdings Inc stock $0.78, price $0.29, upside +169.0%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

XM Xtant Medical Holdings Inc logo Thin data Nov 5, 2026

Xtant Medical Holdings Inc

XTNT · US
Undervalued, but in a downtrend

The stock costs 63% less than our calculation considers fair.

Fair value $0.7800 · Strongly undervalued
Quality 61/100
Healthy Growth (revenue 5y +20.2 %/yr in USD)
Low debt
Even on cautious assumptions the value is 100% above the price ($0.5800).
Loss over the last twelve months · -10.2% net margin (TTM) · fiscal year 2025 3.7%
Mixed vs. peers (6/12)
Negative free cash flow over the last twelve months
Narrow moat 21/100 · thin data
Thin data
Watch Xtant Medical Holdings Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.39 $0.2751 Fair Value $0.7800 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $0.2751 – $1.39 · fair‑value band $0.5800 – $0.9700 · the $0.2900 price screens below the $0.7800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Xtant Medical Holdings in your weekly email

Every Wednesday you see whether Xtant Medical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.

Show moreShow less

It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.

In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain.

The company is headquartered in Belgrade, Montana.

Stock analysis

Xtant Medical Holdings Inc (XTNT) currently trades at $0.2900, while our model-based Fair Value estimate is $0.7800, implying the stock looks roughly 63% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $1.50 per share, and 23 of the 24 models we run sit above the $0.2900 price.

Bear case: the Asset-Based group reads lowest at $0.2500, and 1 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.5800 (bear) to $0.9700 (bull), the price of $0.2900 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Xtant Medical Holdings Inc reported revenue of $134M in FY2025 versus $55.3M in FY2021, a compound +24.8%/yr. Reported net income was $5.0M in FY2025.

Key figures

Market cap $40.7M Micro · P/S ratio 0.36 · EPS (TTM) $−0.0800 · Net margin −10.2% · Return on equity −25.2% · Return on assets (EBIT) −6.9% (5-year average) · Operating margin −18.1% · Revenue (TTM) $110M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 169%, XTNT screens cheaper than that median.

Fair Value models

Bear $0.5800 Fair Value $0.7800 Bull $0.9700
Price $0.2900 · Upside +169.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $1.14 $1.98 $3.36 78
Growth DCF $1.13 $1.88 $3.06 77
Owner Earnings $0.6800 $1.16 $1.96 74
All 24 models by family
DCF Models
FCF DCF $1.14 $1.98 $3.36 78
Owner Earnings $0.6800 $1.16 $1.96 74
5Y Revenue Exit $0.7200 $1.12 $1.65 72
5Y EBITDA Exit $0.9800 $1.66 $2.51 74
5Y P/E Exit $0.7700 $1.22 $1.73 70
10Y Revenue Exit $0.8400 $1.27 $1.88 66
10Y EBITDA Exit $1.03 $1.65 $2.59 67
10Y P/E Exit $0.8900 $1.34 $1.95 63
Earnings-Based
Graham-Dodd $0.2400 $1.14 $1.56 64
Lynch FV $0.3000 $0.4300 $0.5600 61
PEG = 1.0 $0.3000 $0.4300 $0.5600 57
EPV $0.3800 $0.4300 $0.4700 74
Multiples
P/E Multiple $0.5800 $0.7800 $0.9700 63
P/S Multiple $0.4500 $0.6000 $0.7500 58
P/B Multiple $0.5600 $0.7500 $0.9300 55
EV/EBIT $0.5800 $0.8000 $1.02 66
EV/EBITDA $0.8500 $1.16 $1.48 67
EV/Revenue $0.3900 $0.5900 $0.7900 53
Asset-Based
NCAV (Graham) $0.1600 $0.2500 $0.3100 54
Growth DCF
Growth DCF $1.13 $1.88 $3.06 77
Rev-Margin DCF $0.7200 $1.12 $1.64 72
Economic Profit
Residual Income $0.3100 $0.3400 $0.4100 71
ROIC Compounder $0.3800 $0.4900 $0.6200 72
Growth Earnings
Growth-Adj P/E $0.4900 $0.7000 $0.9100 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 62
How much profit the company makes from its sales and capital
Quality Growth 92
Are margins and returns getting better?
Cashflow 65
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Start year 2020 (pandemic). Over 10 years: +8.5% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.6%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+78.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+78.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 5%
⚠ Revenue per share shrinking 35.6%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−16.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.1%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −18.1% a year for the price and −1.3% for the forecasts.
Forecast 2026 (sales)−25.8%
Forecast 2027 (sales)+10.9%
Projected 2028 (sales)+9.8%
Projected 2029 (sales)+8.6%
Projected 2030 (sales)+7.5%

Watch XTNT, get fair value alerts →

Compare Xtant Medical Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside +169.0% · Top 25%
Profitability
Return on assets 5.3% · Above median
Net margin (12 months) −10.2% · Bottom 25%
Operating margin (12 months) −18.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −35.0% · Bottom 25%
Balance sheet
Debt / equity 0.22× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.80× · Cheapest 25%
P/S (12 months) 0.37× · Cheapest 25%
Price / free cash flow (fiscal year) 4.0× · Cheapest 25%
PEG 1.74× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)89 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs XTNT
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs XTNT
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs XTNT
DexCom, Inc DXCM $79.41 $87.35 +10% vs XTNT
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs XTNT
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs XTNT
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs XTNT
Abbott Laboratories, ABT $109.93 $75.28 −32% vs XTNT
Medtronic plc MDT $101.80 $65.61 −36% vs XTNT
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs XTNT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xtant Medical Holdings Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Xtant Medical Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/XTNT

Frequently asked questions

Is Xtant Medical Holdings Inc (XTNT) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $0.7800 versus a price of $0.2900, about +169% upside (undervalued).
What is the fair value of XTNT?
Our model-based fair value for Xtant Medical Holdings Inc is $0.7800 (as of Nov 5, 2026), built from audited fundamentals. The current price: $0.2900.
What is the quality score of XTNT?
Xtant Medical Holdings Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xtant Medical Holdings Inc (XTNT)?
Our model-based price target is the fair value of $0.7800 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $0.5800, optimistic scenario $0.9700. It is a calculation from audited fundamentals, not an analyst target.
What is the Xtant Medical Holdings Inc stock forecast for 2026?
Our models put fair value at $0.7800, about +169% upside versus a price of $0.2900 (undervalued). Cautious scenario $0.5800, optimistic scenario $0.9700. The calculation is refreshed regularly with new filings.
What is the revenue of Xtant Medical Holdings Inc (XTNT)?
Xtant Medical Holdings Inc reported trailing-twelve-month revenue of about $110M (latest available figure, as of Nov 5, 2026).
What growth is priced into Xtant Medical Holdings Inc (XTNT)?
For today's price to be fair in a discounted-cash-flow model, Xtant Medical Holdings Inc would have to grow free cash flow by -16.1 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.2 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of XTNT use?
Our models discount Xtant Medical Holdings Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xtant Medical Holdings Inc that is -16.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Xtant Medical Holdings Inc (XTNT) delivered so far?
Over the past 5 years revenue at Xtant Medical Holdings Inc grew +20.2 % a year. The price currently implies free-cash-flow growth of -16.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Xtant Medical Holdings Inc (XTNT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Xtant Medical Holdings Inc (-16.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Xtant Medical Holdings Inc (XTNT)?
The free-cash-flow yield on the price is 24.99 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Xtant Medical Holdings Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Xtant Medical Holdings Inc (XTNT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xtant Medical Holdings Inc it is $0.7800 per share (as of Nov 5, 2026), against a price of $0.2900. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Xtant Medical Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, XTNT trades below its calculated fair value: price $0.2900, fair value $0.7800, a gap of about +169% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XTNT?
No. The price is what the market pays today ($0.2900); the fair value is what the company's own numbers justify ($0.7800). For Xtant Medical Holdings Inc the two are $0.4900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xtant Medical Holdings Inc worth?
The market values Xtant Medical Holdings Inc at about $40.7M (market capitalisation, as of Nov 5, 2026). Per share that is $0.2900; our models calculate a fair value of $0.7800 per share.
What do the bullish and bearish scenarios say about XTNT?
Our models span a range for Xtant Medical Holdings Inc: cautious scenario $0.5800, base $0.7800, optimistic $0.9700 per share (as of Nov 5, 2026, price $0.2900). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of XTNT?
The PEG ratio of Xtant Medical Holdings Inc is 1.74 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Xtant Medical Holdings Inc (XTNT)?
Balance-sheet figures for Xtant Medical Holdings Inc (as of Nov 5, 2026): return on equity −25.2%, debt of 0.22 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is XTNT from its 52-week high?
Xtant Medical Holdings Inc trades at $0.2900, about 64% below its 52-week high of $0.8100 and 5% above the low of $0.2751 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7800 is for.
Which stocks are comparable to Xtant Medical Holdings Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xtant Medical Holdings Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $0.2900, calculated fair value $0.7800 (+169%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XTNT calculated?
We run Xtant Medical Holdings Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.7800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Xtant Medical Holdings Inc currently trades 63% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xtant Medical Holdings Inc (XTNT)?
The closing price on Nov 6, 2026 was $0.2900. Our model-based fair value is $0.7800, about +169% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xtant Medical Holdings Inc right now?
The price is below even our cautious bear case ($0.5800). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Xtant Medical Holdings Inc

How large is the market capitalisation of Xtant Medical Holdings Inc (XTNT)?
The market capitalisation of Xtant Medical Holdings Inc is $40.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xtant Medical Holdings Inc (XTNT)?
The price-to-sales ratio of Xtant Medical Holdings Inc is 0.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xtant Medical Holdings Inc (XTNT)?
Earnings per share at Xtant Medical Holdings Inc are $−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Xtant Medical Holdings Inc (XTNT)?
The net margin of Xtant Medical Holdings Inc is −10.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xtant Medical Holdings Inc (XTNT)?
The return on equity (ROE) of Xtant Medical Holdings Inc is −25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xtant Medical Holdings Inc (XTNT)?
On an EBIT basis the return on assets of Xtant Medical Holdings Inc is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xtant Medical Holdings Inc (XTNT)?
The operating margin of Xtant Medical Holdings Inc is −18.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xtant Medical Holdings Inc (XTNT)?
Revenue at Xtant Medical Holdings Inc is growing −35.0% versus a year earlier (3y avg +32.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Xtant Medical Holdings Inc (XTNT) carry?
The net debt of Xtant Medical Holdings Inc is $11.7M (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Xtant Medical Holdings Inc in the live analysis

One click puts Xtant Medical Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.